Evidence map›Paper›PMID 38320797›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2024

[Clinical significance and research progress of quantitative hepatitis B virus core antibody measurement].

Y Q Liu, C Zhang, H Zhao, G Q Wang

Open access · greenAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Y Q LiuDepartment of Infectious Disease and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China.
C ZhangDepartment of Infectious Disease and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China.
H ZhaoDepartment of Infectious Disease and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China Department of Infectious Disease, Peking University International Hospital, Beijing 102206, China.
G Q WangDepartment of Infectious Disease and the Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China Department of Infectious Disease, Peking University International Hospital, Beijing 102206, China Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing 100044, China.
Peking University · CN

Funding

General Program of National Natural Science Foundation of China 82270626
6 · The paper itself

Abstract

Hepatitis B virus core antibodies are specific antibodies produced after viral infection that appear early and last for a long time, and its levels in serum are measured by the double-antigen sandwich chemiluminescent microparticle immunoassay method, which has higher sensitivity and specificity, providing new clinical indicators for hepatitis B patients diagnosis, treatment, and drug withdrawal management. This article reviews the clinical significance and research progress of quantitative hepatitis B core antibody measurement and expounds on its research applications and prospects in clinical practice.

Indexed as

Hepatitis BHepatitis B virusClinical RelevanceHepatitis B AntibodiesHepatitis B Core AntigensHumansHepatitis B AntibodiesHepatitis B Core AntigensLiver fibrosisLiver inflammationQuantitative hepatitis B core antibodyReactivationRecurrence

Identifiers

PMID38320797
PMCPMC12814794
OpenAlexW4394739659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.